Studie

A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin ( PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutat

Erkrankungsgruppe:

Leukämien und MDS

Organsystem:

Blut

Stadium:

Ersterkrankung

Standort:

Essen

EudraCT:

2017-004830-28

Prüfplan-Code:

CPKC412A2218

Phase:

II

Prüfsubstanz:

Midostaurin, Fludarabine, Cytarabine, Daunorubicin liposomal or daunorubicin or idarubicin, Mitoxantrone, Etoposide

Sponsor:

Novartis Pharmaceuticals